S. Lani Jasper-Trotter

Quantitative Mass Spectrometry, Drug Discovery and Development

Secretory phospholipase A2 as a trigger for drug release in the treatment of triple-negative breast cancer


Conference paper


Shanese L Jasper, Elena B Skarupa, Brian S Cummings, Robert D Arnold
Cancer Research, vol. 79, The American Association for Cancer Research, 2019, pp. 991--991

Cite

Cite

APA   Click to copy
Jasper, S. L., Skarupa, E. B., Cummings, B. S., & Arnold, R. D. (2019). Secretory phospholipase A2 as a trigger for drug release in the treatment of triple-negative breast cancer. In Cancer Research (Vol. 79, pp. 991–991). The American Association for Cancer Research.


Chicago/Turabian   Click to copy
Jasper, Shanese L, Elena B Skarupa, Brian S Cummings, and Robert D Arnold. “Secretory Phospholipase A2 as a Trigger for Drug Release in the Treatment of Triple-Negative Breast Cancer.” In Cancer Research, 79:991–991. The American Association for Cancer Research, 2019.


MLA   Click to copy
Jasper, Shanese L., et al. “Secretory Phospholipase A2 as a Trigger for Drug Release in the Treatment of Triple-Negative Breast Cancer.” Cancer Research, vol. 79, The American Association for Cancer Research, 2019, pp. 991–91.


BibTeX   Click to copy

@inproceedings{jasper2019a,
  title = {Secretory phospholipase A2 as a trigger for drug release in the treatment of triple-negative breast cancer},
  year = {2019},
  journal = {Cancer Research},
  pages = {991--991},
  publisher = {The American Association for Cancer Research},
  volume = {79},
  author = {Jasper, Shanese L and Skarupa, Elena B and Cummings, Brian S and Arnold, Robert D}
}




Follow this website


You need to create an Owlstown account to follow this website.


Sign up

Already an Owlstown member?

Log in